Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
复制标题
黑色素瘤抑制活性（MIA），恶性黑色素瘤的血清学标志物。
DOI：
--
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
R. Buettner
中科院分区：
文献类型：
--
作者：
A. Bosserhoff;D. Dréau;R. Hein;M. Landthaler;W. Holder;R. Buettner
黑色素瘤抑制活性（MIA）最初被鉴定为从恶性黑色素瘤细胞分泌的11 kDa蛋白。我们已经表明，MIA强烈表达在黑色素瘤和黑色素瘤细胞系，但不是在黑素细胞和正常皮肤。我们还观察到MIA mRNA表达与黑素细胞肿瘤的进行性恶性程度相关。通过灵敏的定量ELISA测量血清或血浆中的MIA，并研究MIA血清水平作为恶性黑色素瘤的新标志物的潜力，表明该蛋白可用于监测治疗和随访。本研究采用ELISA法测定了84例II-IV期黑色素瘤患者血中MIA浓度的变化。在治疗期间，对接受多价黑素瘤疫苗（PMV）、干扰素-α-2b（IFN-α 2b）或白细胞介素-2（IL-2）重复注射治疗的患者进行随访。在治疗前，用PMV或IFN-α 2b治疗的患者具有相当低的MIA浓度，而大多数IL-2治疗的患者具有较高的MIA水平。在治疗结束时，对于PMV、IFN-α 2b或IL-2治疗，疾病进展（PD）患者的MIA浓度高于无黑色素瘤临床证据（NPD）患者（分别为3.7 +/- 0.2 vs 11.5 +/- 5.4 ng/ml、3.8 +/- 0.2 vs 8.3 +/- 1.7 ng/ml和2.3 +/- 0.7 vs 20.2 +/- 7.4 ng/ml，p < 0.05）。与在NPD患者中测量的稳定MIA浓度相反，无论治疗如何，在PD患者中观察到MIA水平随时间显著增加。对于PMV和IFN-α 2b治疗的患者，MIA水平的升高明显早于黑素瘤复发的临床诊断。总之，我们的数据表明，MIA血清水平的定量可用于检测临床上明显和不明显的转移性黑色素瘤疾病和监测治疗。
Melanoma inhibitory activity (MIA) was originally identified as an 11 kDa protein secreted from malignant melanoma cells. We have shown that MIA is strongly expressed in melanoma and melanoma cell lines but not in melanocytes and normal skin. We also observed that MIA mRNA expression correlates with progressive malignancy of melanocytic tumors. Measuring MIA in serum or plasma by a sensitive and quantitative ELISA and investigating the potential of MIA serum levels as a novel marker for malignant melanomas showed that the protein can be used to monitor therapy and follow-up. The present study measured the variations in blood concentrations of MIA in 84 patients with stage II-IV melanoma by ELISA. Patients treated with repeated injections of a polyvalent melanoma vaccine (PMV), interferon-alpha-2b (IFN-alpha 2b) or interleukin-2 (IL-2) were followed during treatment duration. Before treatment, patients treated with PMV or IFN-alpha 2b had comparable low MIA concentrations, whereas most IL-2-treated patients had higher MIA levels. At the end of treatment, MIA concentrations were higher in patients with progressive disease (PD) than in patients with no clinical evidence of melanoma (NPD) for PMV, IFN-alpha 2b or IL-2 therapy (3.7 +/- 0.2 vs 11.5 +/- 5.4 ng/ml, 3.8 +/- 0.2 vs 8.3 +/- 1.7 ng/ml, and 2.3 +/- 0.7 vs 20.2 +/- 7.4 ng/ml, respectively, p < 0.05). In contrast to the stable MIA concentrations measured in NPD patients, significant increase in MIA levels were observed in PD patients over time regardless of treatment. For PMV- and IFN-alpha 2b-treated patients, a rise in MIA levels occurred significantly earlier than clinical diagnosis of melanoma recurrence. In conclusion, our data suggest that quantitation of MIA serum levels may be used for detection of both clinically apparent and non-apparent metastatic melanoma disease and for monitoring therapy.
影响因子：
11.2
作者：
T. Sarantou;D. Chi;D. Garrison;A. Conrad;P. Schmid;D. Morton;D. Hoon
通讯作者：
T. Sarantou;D. Chi;D. Garrison;A. Conrad;P. Schmid;D. Morton;D. Hoon